CORRECTION

Correction: NF-κB Is Activated in CD4+ iNKTCells by Sickle Cell Disease and MediatesRapid Induction of Adenosine A2A ReceptorsThe PLOS ONE Staff

The Competing Interests section is incorrect. The Competing Interests section should read:Joshua Field, M.D., M.S., Joel Linden, Ph.D. and David Nathan, M.D. each have consultingagreements with NKT Therapeutics, Inc. Joel Linden, Ph.D. is an inventor on a patent issued tothe University of Virginia, which claims the use of adenosine A2A agonists for the treatment ofsickle cell disease; he owns shares in Adenosine Therapeutics LLC, which licensed this patent.This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Reference1. Lin G, Field JJ, Yu JC, Ken R, Neuberg D, et al. (2013) NF-κB Is Activated in CD4+ iNKT Cells by Sickle

Cell Disease and Mediates Rapid Induction of Adenosine A2A Receptors. PLoS ONE 8(10): e74664.doi:10.1371/journal.pone.0074664 PMID: 24124453

PLOS ONE | DOI:10.1371/journal.pone.0117760 February 6, 2015 1 / 1

OPEN ACCESS

Citation: The PLOS ONE Staff (2015)Correction: NF-κB Is Activated in CD4+

iNKT Cells by Sickle Cell Disease andMediates Rapid Induction of Adenosine A2A

Receptors. PLoSONE 10(2): e0117760.doi:10.1371/journal.pone.0117760

Published: February 6, 2015

Copyright: © 2015 The PLOS ONE Staff. This is anopen access article distributed under the terms of theCreative Commons Attribution License, which permitsunrestricted use, distribution, and reproduction in anymedium, provided the original author and source arecredited.